After adjusted for dyslipidemia and concomitant use of statins and proton pump inhibitors, our results showed that patients with CYP2C19*2/*2 genotype showed significantly increased risk of CR (OR 7.406, 95% CI 0.894–61.361; P = 0.063) as compared with CYP2C19*1/*1homozygotes. This evidence concerns the gene CYP2C19 and metabolic syndrome.